Theralase Technologies Inc. V.TLT

RE:RE:RE:RE:RE:Cancer free patients

[CancerSlayer]

CancerSlayer wrote:

DJDawg wrote:
One day we will know so much more.

For example, I don't know how much they studied iron status of these patients. If you are iron deficient then the cancer cells will be much more avid. Maybe some of the great responders were iron low and that helped as the cancer cells grabbed the ruvidar. Cancer loves iron so much that there have been attempts to look at intentionally making patients iron deficient to slow the cancer growth.

It would definitely be informative to review all of the patients' pre-treatment lab results to identify those who may have had anemia or a low iron status & look for any association between iron status (i.e. Hemoglobin or Ferritin level) & response rate.  

At least theoretically, reducing a patient's iron level (via an already well-established/used therapy called chelation; generally used for iron-overload conditions) could potentially represent one arm of a two-punch knockout of cancer.  In appropriate patients, chelation would control/limit iron levels within cancer cells, hence reducing cancer cell growth.  As you stated, a lower iron level (naturally or via chelation) would also make cancer cells more avid for iron, causing an even higher expression of their transferrin receptors.  Any boost in the expression of transferrin receptors would be a potential boost in both the uptake of our compound & cancer cell kill/efficacy.  Interesting take...all imo.

Addendum:  

Iron is an essential nutrient for a cancer cell's replication/growth.  This excessive hunger for iron causes an upregulation/increase in not only transferrin receptors, but also other transferrin receptor-independent mechanisms/proteins involved in iron uptake by cancer cells.  Therefore, having a low iron environment has the potential to increase either Rutherrin or Ruvidar uptake, making our treatment that much more versatile compared to other available treatments.

One could argue that for those who have a pre-existing iron-deficiency anemia (IDA), our versatile protocol could potentially provide an even more targeted/efficacious therapy for this specific patient population.  This benefit could potentially be further maximized when/if our treatment is used as a synergistic/combo therapy.   Our indications/uses will only broaden...all imo.